6,7-Dimethoxyquinazoline-4-one: High Purity Intermediate for Gefitinib Synthesis | Manufacturer & Supplier

Discover the essential chemical intermediate, 6,7-Dimethoxyquinazoline-4-one, crucial for the synthesis of the targeted cancer therapy drug, Gefitinib. We are a leading manufacturer and supplier in China, ensuring consistent quality and reliable supply for your pharmaceutical production needs. Explore our specifications and request a quote.

Get a Quote & Sample

Key Advantages of Sourcing Our Pharmaceutical Intermediates

Exceptional Purity & Consistency

We guarantee a purity of ≥98% for our 6,7-Dimethoxyquinazoline-4-one, ensuring predictable outcomes in your Gefitinib synthesis. As a dedicated supplier, we focus on lot-to-lot consistency.

Stable Supply Chain from China

Leverage our robust manufacturing capabilities in China to secure a stable and cost-effective supply of this critical API intermediate. We aim to be your go-to manufacturer.

Technical Expertise & Support

Benefit from our deep understanding of chemical synthesis and applications. We are committed to supporting your R&D and production needs when you buy from us.

Primary Applications in Pharmaceutical Synthesis

Gefitinib Synthesis Intermediate

This compound is a direct precursor in the multi-step synthesis of Gefitinib, an essential drug for treating certain types of non-small cell lung cancer. Secure your supply of this vital pharmaceutical intermediate.

Oncology Drug Development

Essential for research and development in new oncology drug candidates that share similar structural motifs. Discover how our high-quality chemicals can support your innovations.

API Manufacturing

Used in the large-scale production of Active Pharmaceutical Ingredients (APIs), ensuring the efficacy and safety of final drug products. Partner with a reliable manufacturer for your API needs.

Custom Synthesis Projects

Applicable in various custom synthesis projects requiring quinazolinone derivatives. We welcome inquiries for specific chemical needs from our esteemed clients.